Pharmacologic treatment can prevent pancreatic injury after ERCP: A meta-analysis

Gastrointestinal Endoscopy

Volumn 51, Issue 1, 2000, Pages 1-7

  Andriulli, Angelo ^a   Leandro, Gioacchino ^a   Niro, Grazia ^a   Mangia, Alessandra ^a   Festa, Virginia ^a   Gambassi, Giovanni ^a   Villani, Maria Rosaria ^a   Facciorusso, Domenico ^a   Conoscitore, Pasquale ^a   Spirito, Fulvio ^a   De Maio, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; GABEXATE MESILATE; OCTREOTIDE; SOMATOSTATIN;

ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HYPERAMYLASEMIA; META ANALYSIS; PAIN; PANCREAS INJURY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033978197     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5107(00)70377-4     Document Type: Article

References (35)

1. ML Freeman DB Nelson S Sherman GB Haber ME Herman PG Dorsher Complications of endoscopic biliary sphincterotomy N Engl J Med 335 1996 909 918
2. S Sherman G. Lehman ERCP and endoscopic sphincterotomy-induced pancreatitis Pancreas 6 1991 350 367
3. PB Cotton G Lehman J Vennes GE Geenen RC Russell WC Meyers Endoscopic sphincterotomy complications and their management: an attempt at consensus Gastrointest Endosc 37 1991 383 393
4. G Cavallini A Tittobello L Frulloni E Masci A Mariani V Di Francesco Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography N Engl J Med 335 1996 919 923
5. N Kuno T Kasugai T Oguri A. Matsuura Study on prevention of complication associated with endoscopic retrograde cholangiopancreatography (ERCP): a controlled trial of a new protease inhibitor, FOY, in hyperamylasemia following endoscopic retrograde cholangiopancreatography Gendai Iryo 10 1978 571 575
6. K Hajiro D Tsujimura R Inoue H Yamamoto T. Yamamoto Effect of FOY on hyperamylasemia after endoscopic retrograde cholangiopancreatography Gendai Iryo 10 1978 1375 1379
7. Y Shimizu H Takahashi M Deura Y Aizawa M Zenitani M Akiba Prophylactic effects of preoperative administration of Gabexate Mesilate (FOY) on post-ERCP pancreatitis Gendai Iryo 11 1979 540 544
8. V Salamon HD Kuntz B. May Wirkung des synthetischen proteinase-inhibitors FOY auf die hyperamylasamie nach ERP KH Grozinger A Schrey RW Wabnitz Proteinasen-inhibition, FOY workshop, 1981 1982 Wolf G & Sohn Dusseldorf, Germany 132 135
9. L Benini G Angelini E Lavarini G Brocco G Cavallini F Merigo Effect of a new enzyme inhibitor (Gabexate Mesilate- FOY) on hyperenzymemia induced by ERCP. A double blind study [abstract] Digestion 32 1985 A165
10. G Borsch M Bergbauer W Nebel G. Sabin Der einfluß von somatostatin auf die amylasespiegel und pankreatitistrate nach ERCP Med Welt 35 1984 109 112
11. GF Cicero R Lauger J Sahel M Manganaro H. Sarles Effect of somatostatin on clinical, biochemical and morphological changes following ERCP Ital J Gastroenterol 17 1985 265 268
12. G Tyden B Nyberg T Sonnenfeld L. Thulin Effect of somatostatin on hyperamylasemia following endoscopic pancreatography Acta Chir Scand 530 1986 43 45
13. M Bordas V Toledo F Mondelo J. Rodès Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy Hormone Res 29 1988 106 108
14. PA Testoni E Masci F Bagnolo A. Tittobello Endoscopic papillo-sphincterotomy: prevention of pancreatic reaction by somatostatin Ital J Gastroenterol 20 1988 70 73
15. A Saari E Kivilaakso T. Schroder The influence of somatostatin on pancreatic irritation after pancreatography. An experimental and clinical study Surg Res Comm 2 1988 271 278
16. G Flati B Porowska P Negro D Flati MG Chiarinelli M. Carboni Efecto de la somatostatina sobre las secuelas de la colangiopancreatografia retrograda endoscopica Rev Esp Enf Ap Digest 74 1988 17 19
17. K Deschner A Kalloo M Collen EL Cattau KA Maher DE Fleischer Somatostatin: an evaluation of its utility as adjunctive medication for ERCP [abstract] Gastrointest Endosc 35 1989 A149
18. M Guelrud S Mendoza L Viera D. Gelrud Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis Gastrointest Endosc 36 1990 44 47
19. B Persson P Slezak S Efendic A. Haggmark Can somatostatin prevent injection pancreatitis after ERCP? Hepato-gastroenterology 39 1992 259 261
20. JM Bordas V Toledo-Pimentel J Llach E Montserrat F Mondelo A Gines Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study Gastrointest Endosc 47 1998 230 234
21. RTP Poon C Yeung CM Lo WK Yuen CL Liu ST. Fan Prophylactic effect of Somatostatin on post-ERCP pancreatitis: a randomized controlled trial Gastrointest Endosc 49 1999 593 598
22. Z Tulassay J. Papp The effect of long acting somatostatin analogue on enzyme changes after endoscopic pancreatography Gastrointest Endosc 37 1991 48 50
23. JM Sternlieb CA Aronchick JN Retig M Dabezies F Saunders E Goosenberg A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis Am J Gastroenterol 87 1992 1561 1566
24. KF Binmoeller AG Harris R Dumas C Grimaldi JP. Delmont Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 33 1992 1129 1133
25. A Russo C Virgilio G Aprile A Magnano S. Cosentino Influenza dell’octreotide sulla reazione pancreatica indotta da colangiopancreatografia retrograda Giorn Ital End Dig 15 1992 139 145
26. PA Testoni F Lella F Bagnolo M Buizza E. Colombo Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy Ital J Gastroenterol 26 1994 431 436
27. R Arcidiacono P Gambitta A Rossi C Grosso M Bini G. Zanasi The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy Endoscopy 26 1994 715 718
28. G Baldazzi C Conti EG Spotti GP Arisi M Scevola F Gobetti Profilassi della pancreatite acuta post ERCP con octreotide Giorn Chir 15 1994 359 362
29. PA Testoni F Lella F Bagnolo S Caporuscio L Cattani E Colombo Long term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater’s papilla Pancreas 13 1996 61 65
30. Z Tulassay Z Dobronte L Pronai T Zagoni L. Juhasz Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography Aliment Pharmacol Ther 12 1998 1109 1112
31. D Arvanitidis J Hatzipanayiotis G Koutsounopoulos E. Frangou The effect of Octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP Hepato-gastroenterology 45 1998 248 252
32. V Hasselblad D. McCrory Meta-analytic tools for medical decision making: a practical guide Med Decis Making 15 1995 81 96
33. A Andriulli G Leandro R Clemente V Festa N Caruso V Annese Metaanalysis of somatostatin, octreotide, and gabexate mesilate in the therapy of acute pancreatitis Aliment Pharmacol Ther 12 1998 237 245
34. R. Rosenthal Meta-analytic procedures for social research 1984 Sage Beverly Hills
35. KF Binmoeller R Dumas AG Harris JP. Delmont Effect of somatostatin analog octreotide on human sphincter of Oddi Dig Dis Sci 37 1992 773 777